MMIRF (MedMira) Tariff Resilience Score: 5/10 (As of Jun. 29, 2026)


What is MedMira Tariff Resilience Score?

MedMira MMIRF +302.48% Tariff Resilience Score is 5 as of Jun. 29, 2026. The stock has 6 warning signs investors should review. Among 1,375 Biotechnology companies, MedMira ranks better than 62.25% on this metric.

MedMira has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

MedMira has MedMira's medical products face moderate tariff risks due to global supply chains. However, healthcare products often receive exemptions, providing some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes MedMira might have Average Resilient.

MedMira  (OTCPK:MMIRF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

MedMira Tariff Resilience Score Related Terms

MMIRF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, MedMira's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where MedMira's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
MedMira (MMIRF) has a Tariff Resilience Score of 5 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, MedMira ranks #519 out of 1375 companies in the Biotechnology industry, placing it in the top 37.7%.
Is MedMira's Tariff Resilience Score too high?
MedMira's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. MedMira's value of 5 is 25% above this industry median. Based on the distribution chart, MedMira ranks #519 out of 1375 companies in the Biotechnology industry, which is above the industry midpoint.
How does MedMira's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MedMira ranks #519 out of 1375 companies for Tariff Resilience Score. This puts MedMira in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. MedMira's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedMira's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedMira's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMira stock overvalued right now?
MedMira (MMIRF) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For MedMira (MMIRF), the current Tariff Resilience Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMira Business Description

Other Exchanges MIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.